You can choose the size of the video you would like to embed below. Next, copy the embed code that is available in the box below. Paste this code on to your website to display the video.
If you experience problems embedding videos, please contact us.
The Wall Street Journal
April 22, 2014 AT 10:35 AM
Valeant Pharmaceuticals has enlisted investor William Ackman in its attempt to acquire rival Allergan, a $46 billion deal that would create a Big Pharma behemoth. But the details of the Ackman/Valeant alliance are as interesting as the deal itself. WSJ's Dana Mattioli explains on MoneyBeat.